Tetragenetics Announces Collaboration with Amgen

  Tetragenetics Announces Collaboration with Amgen

 Exclusive Research License Of Tetragenetics’ Technology For Surface Antigen
                                 Drug Target

Business Wire

CAMBRIDGE, Mass. -- April 02, 2013

Tetragenetics Inc. a 2012 Gates Foundation Phase ll grant recipient and an
emerging biotechnology company engaged in the development of particle-based
vaccines and expression of membrane proteins for drug discovery, reported
today that it has entered into a technology access and exclusive research
license agreement with Amgen for a defined, but undisclosed, surface antigen.

Dr. Ted Clark, Founder and Chief Scientific Officer of Tetragenetics, said,
“Tetragenetics has created a unique capability for making antigens which
enable the discovery and production of novel antibodies that target validated
but previously difficult to produce membrane protein drug targets.”

“One of the central problems that industry faces with an immunopharmacological
approach to these intractable targets is presentation of the right
extracellular domains. Tetragenetics’ discovery technology has distinct and
quantifiable advantages over mammalian cells which, up until now, have been
the principal cell lines available for discovery purposes,” continued Dr.
Clark. “Our agreement with Amgen marks the second major partnership for
Tetragenetics and the first for this specific family of targets.”

“Our collaboration with Amgen validates Tetragenetics’ proprietary drug
discovery platform,” noted John Reilly, V.P. Business Development. “We will be
announcing further collaborations with leading biotech and pharmaceutical
companies as we expand our partnering programs.”

Tetragenetics’ technology enables high density heterologous expression of
recombinant human membrane proteins on the cell surface of Tetrahymena
thermophila. Immunogen preparations of the drug targets can be made in any of
several formats: cell ghosts (“pellicles”), membrane vesicles, lipid rafts, or
partially purified soluble protein. These enriched preparations are designed
to enhance antibody production against the extracellular portions of the
target.

About Tetragenetics. A 2012 Gates Foundation Phase ll recipient, Tetragenetics
has developed a proprietary suite of platform technologies: TetraExpress™,
G-SOME™, and SionX™, which enable overexpression of mammalian membrane
proteins that are difficult or impossible to produce in conventional systems.
The company’s proprietary technology is being utilized to develop antigens for
use as vaccines and as immunogens for antibody discovery. For more
information, please visit: www.tetragenetics.com

Contact:

Tetragenetics Inc.
John Reilly, 617-229-5224
V.P. Business Development
jreilly@tetragenetics.com
or
SGN Public Relations & Marketing
Suzanne Gibbons-Neff, 203-858-1325
suzanne@sgnpr.com